secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zynerba Pharmaceuticals, Inc. (—)
CIK:        0001621443
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-056002
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Zynerba gets 180-day Nasdaq bid-price extension, transfers to Capital Market
----------------------------------------------------------------------------

- Nasdaq granted 180-day extension until Oct 30, 2023 to regain $1 bid price compliance.
- Company's stock transferred from Nasdaq Global Market to Capital Market effective May 4, 2023.
- Will consider reverse stock split to cure deficiency if needed.
- Previously received deficiency notice Nov 1, 2022; failed to cure by May 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621443/000110465923056002/0001104659-23-056002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621443/000110465923056002/tm2314618d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer